US Biosimulation Market (2026-2031)
The US Biosimulation Market was valued at $294.6 Million in 2026 and projected to reach to $442.3 Million by 2031, representing a compound annual growth rate of 14.7%. The US biosimulation market is positioned for sustained growth as pharmaceutical and biotechnology companies increasingly integrate computational modeling into their drug development pipelines.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
US Biosimulation Market Trends and Insights
- The US market is driven by increasing adoption of computational modeling in drug development, regulatory support for in silico methods, and rising demand for cost-effective alternatives to traditional preclinical testing.
- The US pharmaceutical and biotechnology sectors are leveraging biosimulation to accelerate time-to-market and reduce development costs. In the US, biosimulation technologies are becoming integral to regulatory submissions, with the FDA increasingly accepting model-informed drug development approaches.
- The US market benefits from strong investment in research infrastructure, presence of leading biotech hubs, and collaboration between academic institutions and industry players.
- By 2031, the US is expected to maintain its position as a key growth market, driven by continued innovation in physiologically-based pharmacokinetic (PBPK) modeling and systems pharmacology applications. The US biosimulation landscape is characterized by growing adoption across clinical trial optimization, drug safety assessment, and personalized medicine initiatives.
- The US market's expansion reflects broader healthcare trends toward precision medicine and data-driven decision-making in pharmaceutical development..
Key Market Statistics
- CAGR (2026-2031) 14.7% CAGR
- Market Size, 2026 ~USD 294.6 Million
- Forecast, 2031 ~USD 442.3 Million
- Country US
US Biosimulation Market Overview
Market Valuation Growth :
The US biosimulation market is valued at $294.6 million in 2026 and is projected to reach $442.3 million by 2031, representing a robust 14.7% CAGR over the forecast period.
Regulatory Support Driving Adoption :
The FDA and other US regulatory bodies increasingly accept in silico methods and computational modeling for drug development, reducing reliance on traditional animal testing and accelerating time-to-market.
Cost Reduction in Drug Development :
US pharmaceutical companies are leveraging biosimulation to reduce preclinical testing costs and minimize failed clinical trials, making drug development more economically viable and efficient.
Biotech Innovation Hub :
The US biotech sector's concentration of innovation centers, research institutions, and venture capital funding creates a strong ecosystem for biosimulation technology adoption and advancement.
US Biosimulation Market Dynamics
- Regulatory agencies' growing acceptance of in silico methods, combined with pressure to reduce development costs and timelines, creates a favorable environment for market expansion.
- The US market benefits from advanced IT infrastructure, skilled workforce, and significant R&D investments. Looking ahead to 2031, the market will be shaped by technological advancements in artificial intelligence and machine learning applications within biosimulation platforms.
- Increased collaboration between academic institutions, CROs, and pharmaceutical companies will drive innovation and standardization.
- The shift toward personalized medicine and complex biologics will further elevate demand for sophisticated computational modeling solutions across the US healthcare and pharmaceutical sectors..
Related Ecosystem
Healthcare It
- Computed Tomography (CT)
- Machine Learning
- Magnetic Resonance Imaging (MRI)
- Natural Language Processing (NLP)
- Predictive Analytics
- CERNER CORPORATION
- PHILIPS HEALTHCARE
- Oracle Corporation
- GE HealthCare Technologies Inc.
- Siemens healthineers
Key Takeaways
- The US biosimulation market is valued at $294.6 million in 2026 and is forecast to reach $442.3 million by 2031, representing a 14.7% CAGR.
- The US FDA's acceptance of model-informed drug development is accelerating adoption of biosimulation technologies across the pharmaceutical industry.
- The US market is driven by cost reduction, faster drug development timelines, and regulatory support for in silico methods as alternatives to animal testing.
- By 2031, the US is expected to lead in PBPK modeling and systems pharmacology applications, supported by strong biotech infrastructure and R&D investment.
Biosimulation Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | INDIA (Application) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 16.7% from 2026 to 2031 |
| Largest Segment | CONSULTING & ADVISORY (Offering) |
| Market Size Base Year (Billions) | ~USD 4.27 (2026) |
| Revenue Forecast (Billions) | ~USD 9.24 (2031) |
| Segments Covered | Type, Application, Therapeutic Area, Revenue Model, Deployment Model, End User, Offering |
US Biosimulation Market Report Segmentation
7 segment dimensions are covered across the global market.
By Type
- Adme/Toxicology
- Clinical Trial Simulation Software
- Clinical Trials
- Consulting & Advisory
- Data Analysis & Interpretation
- Demand Forecasting & Inventory Management
- Implementation, Training, And Support
- Integrated Software Suites/Platforms
- Lead Identification & Optimization
- Molecular Modeling & Simulation Software
- Other Biosimulation Software
- Other Manufacturing & Supply Chain Management Applications
- Pbpk Modeling & Simulation Software
- Phase I
- Phase Ii
- Phase Iii
- Phase Iv/Post-Marketing Surveillance
- Pk/Pd
- Pk/Pd Modeling & Simulation Software
- Preclinical Testing
- Production Planning & Optimization
- Quality Control & Process Monitoring
- Risk Management & Contingency Planning
- Standalone Modules
- Target Identification & Validation
- Toxicity Prediction Software
By Application
- Disease Modeling
- Drug Development
- Drug Discovery
- Manufacturing & Supply Chain Management
- Other Applications
By Therapeutic Area
- Cardiovascular Diseases
- Infectious Diseases
- Neurological Disorders
- Oncology
- Other Therapeutic Areas
By Revenue Model
- License-Based Models
- Pay-Per-Use Models
- Service-Based Models
- Subscription-Based Models
By Deployment Model
- Cloud-Based Models
- Hybrid Models
- On-Premise Models
By End User
- Academic & Research Institutions
- Contract Research Organizations
- Other End Users
- Pharmaceutical & Biotechnology Companies
- Regulatory Bodies
By Offering
- Services
- Software
Target Audience
- Pharmaceutical Companies : US pharma executives need market intelligence to optimize R&D budgets, evaluate biosimulation platform investments, and understand competitive adoption rates within the industry.
- Biotechnology Firms : Biotech companies require detailed market insights to assess biosimulation adoption trends, identify partnership opportunities, and plan technology integration strategies for drug development.
- Contract Research Organizations (CROs) : US CROs need market data to expand service offerings, understand client demand for biosimulation services, and position themselves competitively in the evolving preclinical landscape.
- Software & Technology Vendors : Biosimulation platform providers require US market analysis to identify growth opportunities, understand customer segments, and develop targeted sales and marketing strategies.
- Healthcare Investors & Consultants : Investment firms and management consultants need comprehensive US market data to evaluate portfolio companies, identify emerging opportunities, and support M&A due diligence activities.
Key Companies in the US Biosimulation Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| SANOFI | France | Public Company | Pediatric and combination vaccines (polio, pertussis, Hib, hexavalent),Other vaccines (RSV, hepatitis A, typhoid, yellow fever, rabies),Immunology and inflammation therapies, |
| CERTARA | United States | Public Company | Biosimulation platforms (Simcyp, Phoenix, NLME, Pirana),Regulatory data and submission software (Pinnacle 21, GlobalSubmit, CoAuthor, Metadata Repository),Discovery and informatics solutions (Chemaxon suite, D360, design tools), |
| DASSAULT SYSTÈMES | France | Public Company | 3D Modeling (CATIA, SOLIDWORKS, GEOVIA, BIOVIA),PLM & Collaboration (ENOVIA, CENTRIC PLM, 3DEXCITE, 3DEXPERIENCE collaboration),Simulation & Manufacturing (SIMULIA, DELMIA, 3DVIA), |
| SCHRöDINGER, INC. | United States | Public Company | Software,Drug Discovery – Collaborations (e.g., Novartis),Drug Discovery – Internal Pipeline, |
| SIMULATIONS PLUS | United States | Public Company | PBPK/PKPD and biopharmaceutics software (GastroPlus, DDDPlus, MembranePlus),QSP and disease-systems platforms (DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, Thales),ADMET Predictor, MedChem Designer and discovery-oriented AI/ML tools, |
| PHYSIOMICS PLC | United Kingdom | Public Company | Oncology modeling & simulation (Virtual Tumour–centric consulting),Broader quantitative pharmacology & computational biology services,Personalized medicine technology and related analytics, |
| INSTEM PLC | United Kingdom | Private Company | Research study management software (discovery, preclinical, early clinical),Regulatory submission and SEND-compliant dataset solutions,In silico and data insights / predictive analytics, |
SANOFI
Sanofi is a French multinational pharmaceutical company founded in 1994 with 74,846 employees. As a public company, it operates globally in the development, manufacturing, and distribution of medicines and vaccines.
CERTARA
Certara is a United States-based public company founded in 2008 with 1,546 employees. It provides software and services for drug development, including modeling, simulation, and regulatory consulting.
DASSAULT SYSTÈMES
Dassault Systèmes is a French software company founded in 1981 with 25,724 employees. As a public company, it develops 3D design, simulation, and digital lifecycle management solutions for various industries.
SCHRöDINGER, INC.
Schrödinger, Inc. is a United States-based public company founded in 1990 with 850 employees. It provides computational chemistry and molecular simulation software platforms for drug discovery and materials science.
SIMULATIONS PLUS
Simulations Plus is a United States-based public company founded in 1996 with 213 employees. It develops software for drug development, including pharmacokinetic and pharmacodynamic modeling and simulation.
PHYSIOMICS PLC
Physiomics PLC is a United Kingdom-based public company founded in 2001 with 10 employees. It specializes in computational biology and systems pharmacology for drug development.
INSTEM PLC
Instem PLC is a United Kingdom-based private company founded in 1969 with 510 employees. It provides software and services for data management and analysis in preclinical and clinical research.
Reasons to Buy this Report
- Market Size & Growth Projections : Access precise US market valuation data ($294.6M in 2026 growing to $442.3M by 2031) with detailed CAGR analysis to inform investment decisions and strategic planning.
- Regulatory Landscape Intelligence : Understand FDA and US regulatory body acceptance of biosimulation methods, enabling companies to align product development strategies with evolving compliance requirements.
- Competitive Positioning Analysis : Identify key players, market share distribution, and competitive dynamics specific to the US market to benchmark performance and identify partnership or acquisition opportunities.
- Sector-Specific Insights : Gain detailed understanding of adoption rates across US pharmaceutical, biotech, and CRO segments, with forecasts for different application areas and therapeutic domains.
- Strategic Decision Support : Leverage comprehensive US market data to support go-to-market strategies, pricing models, and resource allocation decisions for biosimulation solutions and services.
Frequently asked questions
What is the current size of the US biosimulation market?
The US biosimulation market is valued at $294.6 million in 2026 and is projected to grow to $442.3 million by 2031.
What is the growth rate of the US biosimulation market?
The US biosimulation market is expected to grow at a compound annual growth rate (CAGR) of 14.7% from 2026 to 2031.
What are the main drivers of growth in the US biosimulation market?
Key drivers include FDA acceptance of model-informed drug development, cost reduction in drug development, faster time-to-market, regulatory support for in silico methods, and increasing adoption of PBPK modeling and systems pharmacology.
How is the US biosimulation market expected to evolve by 2031?
By 2031, the US market is expected to see increased integration of biosimulation in clinical trial design, drug safety assessment, and personalized medicine, with stronger adoption across pharmaceutical and biotechnology companies.
What role does the FDA play in the US biosimulation market?
The FDA's increasing acceptance of model-informed drug development and in silico methods is a major catalyst for biosimulation adoption in the US, encouraging pharmaceutical companies to invest in these technologies for regulatory submissions.
RESEARCH METHODOLOGY
This research study involved the extensive use of both primary and secondary sources. It involved the analysis of various factors affecting the industry to identify the segmentation types, industry trends, key players, the competitive landscape of market players, and key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies.
Secondary Research
This research study extensively utilized secondary sources, including directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, as well as white papers, annual reports, and companies' house documents. The secondary research aimed to gather and analyze information for a comprehensive and commercially focused study of the biosimulation market, encompassing technical aspects and market dynamics. It also facilitated the identification of key players, market classification, industry trends, geographical markets, and significant market-related developments. Additionally, a database of prominent industry leaders was compiled through secondary research.
Primary Research
In the primary research process, various supply-side and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, engineers, and related key executives from various companies and organizations operating in the biosimulation market. Primary sources from the demand side included personnel from pharmaceutical & biotechnology companies, contract research organizations, academic & research institutes, and regulatory bodies.
A breakdown of the primary respondents is provided below:
Note: Tiers are defined based on a company’s total revenue, as of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million. Other designations include sales managers, marketing managers, and product managers.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the biosimulation market was determined after data triangulation through the two approaches mentioned below. After the completion of each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach.
Biosimulation Market : Top-Down and Bottom-Up Approach
Data Triangulation
The size of the biosimulation market was estimated through segmental extrapolation using the bottom-up approach. The methodology used is as follows: -
- Revenues for individual companies were gathered from public sources and databases.
- Shares of leading players in the biosimulation market were gathered from secondary sources to the extent available. In certain cases, shares of biosimulation businesses were ascertained after a detailed analysis of various parameters, including product portfolios, market positioning, selling price, and geographic reach & strength.
- Individual shares or revenue estimates were validated through interviews with experts.
- The total revenue in the biosimulation market was determined by extrapolating the market share data of major companies.
Market Definition
Biosimulation is a technology that employs computer-aided simulations to replicate and predict the dynamics of biological processes and systems. It uses modern computational power to analyze and model biological behavior through mathematical expressions. Biosimulation, often referred to as Computer-aided Drug Design (CADD), plays a critical role in various stages of drug discovery and development. Leveraging AI and machine learning, biosimulation enhances the evaluation of drug safety, efficacy, and interactions, ultimately streamlining clinical trial design and accelerating time-to-market for new therapeutics.
Key Stakeholders
- Clinical/Physician centers
- Biosimulation vendors
- Clinical research organizations
- Pharmaceutical/Biopharmaceutical companies
- Research & development (R&D) companies
- Business research and consulting service providers
- Medical research laboratories
- Academic medical centers/Universities/Hospitals
- Regulatory agencies
- Clinical researchers
- Accountable care organizations
- Investors and venture capitalists
Report Objectives
- To define, describe, and forecast the biosimulation market based on offering, phase of development, modality, application, therapeutic area, deployment mode, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall biosimulation market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments such as product launches & approvals, partnerships, agreements, and collaborations in the overall biosimulation market
- To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
- Company information
- Detailed analysis and profiling of additional market players (up to 5)
Regional Analysis
- Further breakdown of the Rest of Asia Pacific biosimulation market into Taiwan, New Zealand, Thailand, Singapore, Malaysia, and other countries
- Further breakdown of the Rest of Europe biosimulation market into Russia, Austria, Finland, Sweden, Turkey, Norway, Poland, Portugal, Romania, Denmark, and other countries
Get the Full Biosimulation Market Report
Full forecast, segment splits, and company analysis for all Biosimulation Market.
- Canada Biosimulation Market
- Germany Biosimulation Market
- France Biosimulation Market
- UK Biosimulation Market
- Italy Biosimulation Market
- Spain Biosimulation Market
- China Biosimulation Market
- Japan Biosimulation Market
- India Biosimulation Market
- Australia Biosimulation Market
- South Korea Biosimulation Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report